S&P 500   3,574.85 (+0.49%)
DOW   29,496.73 (+0.80%)
QQQ   290.23 (-0.05%)
AAPL   115.46 (-1.60%)
MSFT   209.71 (-0.32%)
FB   266.50 (-1.19%)
GOOGL   1,725.61 (-0.62%)
AMZN   3,094.64 (-0.15%)
TSLA   522.84 (+6.79%)
NVDA   525.95 (+0.47%)
BABA   269.17 (-0.58%)
CGC   24.00 (+1.18%)
GE   10.23 (+4.82%)
MU   64.18 (+4.53%)
AMD   87.10 (+2.91%)
T   28.50 (+0.64%)
NIO   52.15 (+5.89%)
F   8.92 (+2.06%)
ACB   7.08 (-0.70%)
GILD   59.92 (-0.32%)
NFLX   484.22 (-0.82%)
BA   207.68 (+4.04%)
DIS   142.61 (+1.09%)
S&P 500   3,574.85 (+0.49%)
DOW   29,496.73 (+0.80%)
QQQ   290.23 (-0.05%)
AAPL   115.46 (-1.60%)
MSFT   209.71 (-0.32%)
FB   266.50 (-1.19%)
GOOGL   1,725.61 (-0.62%)
AMZN   3,094.64 (-0.15%)
TSLA   522.84 (+6.79%)
NVDA   525.95 (+0.47%)
BABA   269.17 (-0.58%)
CGC   24.00 (+1.18%)
GE   10.23 (+4.82%)
MU   64.18 (+4.53%)
AMD   87.10 (+2.91%)
T   28.50 (+0.64%)
NIO   52.15 (+5.89%)
F   8.92 (+2.06%)
ACB   7.08 (-0.70%)
GILD   59.92 (-0.32%)
NFLX   484.22 (-0.82%)
BA   207.68 (+4.04%)
DIS   142.61 (+1.09%)
S&P 500   3,574.85 (+0.49%)
DOW   29,496.73 (+0.80%)
QQQ   290.23 (-0.05%)
AAPL   115.46 (-1.60%)
MSFT   209.71 (-0.32%)
FB   266.50 (-1.19%)
GOOGL   1,725.61 (-0.62%)
AMZN   3,094.64 (-0.15%)
TSLA   522.84 (+6.79%)
NVDA   525.95 (+0.47%)
BABA   269.17 (-0.58%)
CGC   24.00 (+1.18%)
GE   10.23 (+4.82%)
MU   64.18 (+4.53%)
AMD   87.10 (+2.91%)
T   28.50 (+0.64%)
NIO   52.15 (+5.89%)
F   8.92 (+2.06%)
ACB   7.08 (-0.70%)
GILD   59.92 (-0.32%)
NFLX   484.22 (-0.82%)
BA   207.68 (+4.04%)
DIS   142.61 (+1.09%)
S&P 500   3,574.85 (+0.49%)
DOW   29,496.73 (+0.80%)
QQQ   290.23 (-0.05%)
AAPL   115.46 (-1.60%)
MSFT   209.71 (-0.32%)
FB   266.50 (-1.19%)
GOOGL   1,725.61 (-0.62%)
AMZN   3,094.64 (-0.15%)
TSLA   522.84 (+6.79%)
NVDA   525.95 (+0.47%)
BABA   269.17 (-0.58%)
CGC   24.00 (+1.18%)
GE   10.23 (+4.82%)
MU   64.18 (+4.53%)
AMD   87.10 (+2.91%)
T   28.50 (+0.64%)
NIO   52.15 (+5.89%)
F   8.92 (+2.06%)
ACB   7.08 (-0.70%)
GILD   59.92 (-0.32%)
NFLX   484.22 (-0.82%)
BA   207.68 (+4.04%)
DIS   142.61 (+1.09%)
Log in
TSE:MDNA

Medicenna Therapeutics Corp. (MDNA.TO) Stock Forecast, Price & News

C$4.84
-0.04 (-0.82 %)
(As of 11/23/2020 10:34 AM ET)
Add
Compare
Today's Range
C$4.80
Now: C$4.84
C$4.88
50-Day Range
C$4.80
MA: C$5.27
C$5.90
52-Week Range
C$1.30
Now: C$4.84
C$7.25
Volume4,950 shs
Average Volume93,549 shs
Market CapitalizationC$237.16 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Medicenna Therapeutics Corp., a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines (EC) and Superkines for the treatment of cancer. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that is in the Phase 2b clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA57 for solid tumors and non-malignant cells of the tumor micro-environment; MDNA109, an IL-2 agonist to treat cancer immunotherapies; MDNA209, an IL-2 antagonist for autoimmune diseases; MDNA413, a dual IL-4/IL-13 antagonist for the treatment of solid tumors, atopic dermatitis, asthma, and fibrosis; and MDNA132, an IL-13 agonist to treat solid tumors and IL 13Ralpha2 chimeric antigen receptor T cell. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-403-6807898
Employees7

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowC$0.69 per share
Book ValueC$0.74 per share

Profitability

Miscellaneous

Market CapC$237.16 million
Next Earnings DateN/A
OptionableNot Optionable
C$4.84
-0.04 (-0.82 %)
(As of 11/23/2020 10:34 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MDNA News and Ratings via Email

Sign-up to receive the latest news and ratings for MDNA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Medicenna Therapeutics Corp. (MDNA.TO) (TSE:MDNA) Frequently Asked Questions

How has Medicenna Therapeutics Corp. (MDNA.TO)'s stock price been impacted by COVID-19 (Coronavirus)?

Medicenna Therapeutics Corp. (MDNA.TO)'s stock was trading at C$3.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MDNA shares have increased by 60.3% and is now trading at C$4.84.
View which stocks have been most impacted by COVID-19
.

What stocks does MarketBeat like better than Medicenna Therapeutics Corp. (MDNA.TO)?

Wall Street analysts have given Medicenna Therapeutics Corp. (MDNA.TO) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Medicenna Therapeutics Corp. (MDNA.TO) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Medicenna Therapeutics Corp. (MDNA.TO)'s key competitors?

What other stocks do shareholders of Medicenna Therapeutics Corp. (MDNA.TO) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medicenna Therapeutics Corp. (MDNA.TO) investors own include OPKO Health (OPK), AbbVie (ABBV), Livongo Health (LVGO), Aptose Biosciences (APTO), Antibe Therapeutics Inc. (ATE.V) (ATE), Birchcliff Energy Ltd. (BIR.TO) (BIR), CVS Health (CVS), Freehold Royalties Ltd. (FRU.TO) (FRU), Fastly (FSLY) and Inovio Pharmaceuticals (INO).

Who are Medicenna Therapeutics Corp. (MDNA.TO)'s key executives?

Medicenna Therapeutics Corp. (MDNA.TO)'s management team includes the following people:
  • Dr. Fahar Merchant, Founder, Chairman, CEO & Pres (Age 63, Pay $410.99k)
  • Ms. Rosemina Merchant, Founder, Chief Devel. Officer & Director (Age 63, Pay $319.88k)
  • Ms. Elizabeth Williams C.A., CPA, CPA, CA, CFO & Corp. Sec. (Age 42, Pay $225k)
  • Dr. John H. Sampson M.D., Ph.D., MBA, Chief Clinical Advisor
  • Dr. Martin Bexon M.D., Head of Clinical Devel.
  • Dr. Samuel R. Denmeade, Scientific Advisor

What is Medicenna Therapeutics Corp. (MDNA.TO)'s stock symbol?

Medicenna Therapeutics Corp. (MDNA.TO) trades on the Toronto Stock Exchange (TSX) under the ticker symbol "MDNA."

How do I buy shares of Medicenna Therapeutics Corp. (MDNA.TO)?

Shares of MDNA and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Medicenna Therapeutics Corp. (MDNA.TO)'s stock price today?

One share of MDNA stock can currently be purchased for approximately C$4.84.

How big of a company is Medicenna Therapeutics Corp. (MDNA.TO)?

Medicenna Therapeutics Corp. (MDNA.TO) has a market capitalization of C$237.16 million. Medicenna Therapeutics Corp. (MDNA.TO) employs 7 workers across the globe.

What is Medicenna Therapeutics Corp. (MDNA.TO)'s official website?

The official website for Medicenna Therapeutics Corp. (MDNA.TO) is www.medicenna.com.

How can I contact Medicenna Therapeutics Corp. (MDNA.TO)?

Medicenna Therapeutics Corp. (MDNA.TO)'s mailing address is 2440 Kensington Rd NW, CALGARY, AB T2N 3S1, Canada. The company can be reached via phone at +1-403-6807898.

This page was last updated on 11/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.